Significantly more potent than other commercially available proteasome inhibitors; IC50 values in the low to mid nM range. 3-log specificity for the inhibition of proteasome proteolytic activities as compared to other proteases such as chymotrypsin, trypsin, catharsis A, and catharsis B. W.....
[更多]
Development of more effective therapeutics against human ovarian cancerTreatment for advanced-stage ovarian cancer with recurrent disease or failed first-line chemotherapySuperior safety profile with little to no side effects
[更多]
Compounds already have a proven safety profile Treatment for DRA would occur during normal dialysis treatment directly into patient blood where fibrils are found
[更多]
| |< <- | [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] | -> >| |
